Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Loss of RESponse to Ustekinumab Treated by Dose Escalation (REScUE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04245215
Recruitment Status : Recruiting
First Posted : January 28, 2020
Last Update Posted : February 25, 2020
Sponsor:
Collaborator:
Janssen Cilag N.V./S.A.
Information provided by (Responsible Party):
Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW

Brief Summary:
The aim of the study is to investigate the effect of re-induction with ustekinumab ≈6mg/kg IV followed by two different maintenance dosing regimens 90 mg subcutaneous every 8 weeks (Q8W) vs 90 mg subcutaneous every 4 weeks(Q4W) on clinical, biological and pharmacological outcomes in patients with Crohn's disease who show a secondary loss of response over time

Condition or disease Intervention/treatment Phase
Crohn Disease Drug: Ustekinumab Phase 3

Detailed Description:
The study is a prospective double blind interventional study in patients with Crohn Disease treated with ustekinumab that show an objective secondary loss of response to ustekinumab after induction treatment (>Week 16). Patients can be screened during a four week period. The screening includes a clinical, biochemical and endoscopic assessment. Patients will be randomized 8 weeks after the last subcutaneous injection with ustekinumab. All patient will receive an intravenous re-induction with ustekinumab ≈6mg/kg at baseline (8 weeks after last subcutaneous administration). After the intravenous re-induction, the patients receive either ustekinumab 90 mg subcutaneous Q4W or Q8W (altered with q8w placebo to mimic Q4W injections) till week 48. Clinical and biochemical evaluation will be planned every 8 weeks until week36 with a final evaluation at week48. Primary endpoint will be assessed at week 48. Final assessment at week 48 will include clinical, biochemical and endoscopic evaluation.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 108 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Loss of RESponse to Ustekinumab Treated by Dose Escalation
Actual Study Start Date : February 13, 2020
Estimated Primary Completion Date : October 2022
Estimated Study Completion Date : October 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Crohn's Disease
Drug Information available for: Ustekinumab

Arm Intervention/treatment
Placebo Comparator: 1. Subcutaneous ustekinumab every 8 weeks
re-induction (≈6mg/kg) intravenous ustekinumab followed by 90 mg Subcutaneous ustekinumab every 8 weeks (Q8W) for 48 weeks - receiving Q8W placebo to mimic Q4W injections
Drug: Ustekinumab
re-induction and dose escalation form every 8 weeks to every 4 weeks only in arm 2
Other Name: dose escalation only in arm 2

Active Comparator: 2. Subcutaneous ustekinumab every 4 weeks
re-induction (≈6mg/kg) intravenous ustekinumab followed by 90 mg Subcutaneous ustekinumab every 4 weeks (Q4W) for 48 weeks
Drug: Ustekinumab
re-induction and dose escalation form every 8 weeks to every 4 weeks only in arm 2
Other Name: dose escalation only in arm 2




Primary Outcome Measures :
  1. Proportion of patients with steroid free clinical remission and fecal calprotectin<250µg/g at week 48 [ Time Frame: week 48 ]
    Proportion of patients with steroid free clinical remission (patient reported outcome-2 remission: abdominal pain ≤ 1 AND stool frequency ≤ 3) and fecal calprotectin<250µg/g at week 48. [stool frequency (ST): average number of liquid stools for 1 week abdominal pain (AP): average scoring for abdominal pain for 1 week (0=none; 1=mild, 2=moderate; 3= severe)]


Secondary Outcome Measures :
  1. Proportion of patients with complete endoscopic remission at week 48 [ Time Frame: week 48 ]
    Proportion of patients with complete endoscopic remission (simple endoscopic score for Crohn's disease (SES-CD )<3) at week 48

  2. Proportion of patients with endoscopic remission at week 48 [ Time Frame: week 48 ]
    Proportion of patients with endoscopic remission (simple endoscopic score for Crohn's disease (SES-CD) <5) at week 48

  3. Proportion of patients with endoscopic response at week 48 [ Time Frame: week 48 ]
    Proportion of patients with endoscopic response (≥50% decrease in simple endoscopic score for Crohn's disease (SES-CD)) at week 48

  4. Proportion of patients with clinical remission at week 48 [ Time Frame: week 48 ]
    Proportion of patients with clinical remission (patient reported outcome-2 remission: abdominal pain ≤ 1 AND stool frequency ≤ 3) at week 48

  5. Proportion of patients with biomarker remission at week 48 [ Time Frame: week 48 ]
    Proportion of patients with biomarker remission (C-reactive protein <5 mg/L and fecal calprotectin <250 µg/g) at week 48

  6. Proportion of patients with at all time points after baseline ustekinumab trough concentration > 1.4 μg/mL [ Time Frame: between baseline and week 48 ]
    Proportion of patients with at all time points after baseline ustekinumab trough concentration > 1.4 μg/mL

  7. Proportion of patients with serious adverse events at week 48 [ Time Frame: Week 48 ]
    Proportion of patients with serious adverse events at week 48



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. ≥18 years
  2. Diagnosis of Crohn's disease by endoscopic and/or radiologic examination.
  3. Patient currently treated with ustekinumab, independent of previous biological exposure.
  4. Patients treated with maintenance dose of ustekinumab subcutaneous 90 mg every 8 weeks
  5. Documented primary response at any time point after induction (week 16) and during maintenance defined as a clinical response (physician discretion) AND confirmed by either any of the following:

    a. if biomarker elevated at start of ustekinumab (C-reactive protein>5 mg/l or fecal calprotectin >250µg/g): i. decrease of C-reactive protein by 50 % or more compared to baseline( prior to ustekinumab induction) ii. C-reactive protein <5 mg/l iii. decrease of fecal calprotectin by 50 % or more compared to baseline( prior to ustekinumab induction) iv. fecal calprotectin<250µg/g b. Documented mucosal healing (simple endoscopic score for Crohn's disease (SES-CD)<3)

  6. Documented loss of response after induction (> week 16) assessed by the physician as Moderate to severe active Crohn's disease, defined as Patient Reported Outcome-2 (Abdominal Pain > 1 AND Stool Frequency > 3) AND C-reactive protein and/or fecal calprotectin increased by 25 % or more compared to the lowest value under ustekinumab treatment (C-reactive protein>5 mg/L and/or fecal calprotectin>250µg/g).
  7. Presence of mucosal ulcers in at least one segment of the ileum or colon and a simple endoscopic score for Crohn's disease (SES-CD) ≥6 (for patients with isolated ileitis ≥4), as assessed by ileocolonoscopy
  8. Adequate contraception in female of reproductive age
  9. Have the capacity to understand and sign an informed consent form.
  10. Be able to adhere to the study visit schedule and other protocol requirements.

Exclusion Criteria:

  1. Ongoing treatment with

    1. other concomitant biological (vedolizumab, anti-TNF)
    2. Steroids >20 mg prednisolone or equivalent at baseline (budesonide >6 mg)
    3. Patient already receiving ustekinumab every 4 weeks
  2. Women that are pregnant, nursing, or planning pregnancy
  3. Have screening laboratory test results within the following parameters:

    1. Haemoglobin < 8.5 g/dL
    2. Platelets < 100,000 /mm3
    3. Serum creatinine ≥ 1.7 mg/dL
    4. aspartate aminotransferase and alanine aminotransferase > 3 times the upper limit of normal range
    5. Direct (conjugated) bilirubin ≥ 3.0 mg/dL.
  4. Have current signs or symptoms of infection confirmed by positive stool or blood testing (including gastrointestinal pathogens, tuberculosis, human immunodeficiency virus, hepatitis B, hepatitis C).
  5. Patients with a positive stool sample for gastrointestinal pathogen including Clostridium difficile.
  6. Evidence of current or previous clinically significant disease, medical condition other than Crohn's Disease, finding of the medical examination, or laboratory value at the screening visit outside the reference range that is of clinical relevance, that in the opinion of the Investigator, would compromise the safety of the patient or the quality of the data.
  7. Patients with an ileostomy
  8. Patients that received an intravenous re-induction with ustekinumab within the 6 months prior to baseline.
  9. Patients with an impassable stenosis even after attempt of endoscopic balloon dilation.
  10. Patients with an abscess

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04245215


Contacts
Layout table for location contacts
Contact: Saskia Appelmans +320499566221 ext +320499566221 saskia.appelmans@birdgroup.be

Locations
Layout table for location information
Belgium
Saskia Appelmans Recruiting
Deinze, Belgium, 9850
Sponsors and Collaborators
Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW
Janssen Cilag N.V./S.A.
Investigators
Layout table for investigator information
Principal Investigator: Peter Bossuyt, MD BIRD (Belgian IBD Research and Development) vzw

Layout table for additonal information
Responsible Party: Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW
ClinicalTrials.gov Identifier: NCT04245215    
Other Study ID Numbers: BIRD2018001
First Posted: January 28, 2020    Key Record Dates
Last Update Posted: February 25, 2020
Last Verified: February 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW:
dose escalation
ustekinumab
Additional relevant MeSH terms:
Layout table for MeSH terms
Crohn Disease
Inflammatory Bowel Diseases
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases
Ustekinumab
Dermatologic Agents